Latest Articles

Publication Date
Epigenetic Compound Library Screen Identifies Ibrutinib as an Inhibitor of Ovarian Clear Cell Carcinoma Viability.

Ovarian clear cell carcinoma (OCCC) is an endometriosis-associated ovarian cancer subtype. Somatic mutations in OCCC are reported in ARID1A, PIK3CA, and the TERT promoter (TERTp), as well as less commonly …

Published: April 10, 2026, midnight
Endometriosis and Endometrial Cancer-Association Between Biological Mechanisms and Its Clinical Implications.

Endometriosis and endometrial cancer are distinct gynecological conditions that share overlapping biological mechanisms with implications for clinical management. Endometriosis is a chronic, benign disorder characterized by the ectopic implantation of …

Published: April 10, 2026, midnight
Targeting inflammation in endometriosis: emerging therapeutic options.

Endometriosis is a chronic, estrogen-dependent inflammatory disease affecting up to 10% of reproductive-aged women. Current therapies are predominantly hormone-based and offer symptomatic relief without correcting the immune dysregulation and inflammation …

Published: Dec. 24, 2025, midnight
Endometriosis as an immune-mediated disease: pathogenetic mechanisms and therapeutic strategies.

Endometriosis, which affects approximately 10% of women of reproductive age, is a complex inflammatory disease with significant immune system disturbances caused by an inadequate immune response to retrograde menstruation and …

Published: Dec. 18, 2025, midnight
Ovarian squamous cell carcinoma: clinicopathological features, prognosis and immunotherapy outcomes.

To explore the characteristics and survival outcomes of ovarian squamous cell carcinoma (SCC) and the treatment effectiveness of immune checkpoint inhibitors (ICIs).

Published: Dec. 17, 2025, midnight
The immunotherapy era in ovarian clear cell carcinoma: current evidence and future perspective.

Ovarian clear cell carcinoma (OCCC) is a rare, aggressive epithelial ovarian cancer subtype, accounting for approximately 10% of cases and associated with a poor prognosis due to chemoresistance and unique …

Published: Nov. 26, 2025, midnight
Correction: Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis.

[This corrects the article DOI: 10.3389/fimmu.2021.641206.].

Published: Nov. 24, 2025, midnight
Case Report: Diagnostic challenges in cervical small cell neuroendocrine carcinoma of a reproductive-age woman.

Small cell neuroendocrine carcinoma of the cervix (SCNEC) is a rare and highly aggressive malignancy with a poor prognosis. We report the case of a 36-year-old nulliparous woman with a …

Published: Nov. 10, 2025, midnight
Nanodrug impact on female reproductive health and fetal development: From translation approaches to long-term safety concern.

Biomaterials for drug delivery offer significant advantages over conventional medications, including enhanced cellular uptake, improved drug stability, targeted delivery, and controlled drug release. Cutting-edge nanodrugs delivery approaches such as drugs …

Published: Nov. 5, 2025, midnight
Macrophages in endometriosis: key roles and emerging therapeutic opportunities-a narrative review.

Endometriosis is a chronic gynecological disorder affecting approximately 10% of women of reproductive age. It commonly presents with pelvic pain, dysmenorrhea, and infertility, imposing substantial physical, psychological, and social burdens. …

Published: Oct. 21, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!